User profiles for Bhumsuk Keam
 | Bhumsuk KeamDepartment of Internal Medicine, Seoul National University Hospital Verified email at snu.ac.kr Cited by 17098 |
[HTML][HTML] Cabozantinib versus everolimus in advanced renal-cell carcinoma
…, BJ Roth, GA Bjarnason, L Géczi, B Keam… - … England Journal of …, 2015 - Mass Medical Soc
Background Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets
vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which …
vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which …
[HTML][HTML] Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from …
Purpose Treatment with pembrolizumab, an anti–programmed death-1 antibody, at 10 mg/kg
administered once every 2 weeks, displayed durable antitumor activity in programmed …
administered once every 2 weeks, displayed durable antitumor activity in programmed …
[HTML][HTML] Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600–mutant anaplastic thyroid cancer
…, D Wang, F Rangwala, B Keam - Journal of Clinical …, 2018 - ncbi.nlm.nih.gov
Purpose We report the efficacy and safety of dabrafenib (BRAF inhibitor) and trametinib (MEK
inhibitor) combination therapy in BRAF V600E–mutated anaplastic thyroid cancer, a rare, …
inhibitor) combination therapy in BRAF V600E–mutated anaplastic thyroid cancer, a rare, …
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer
…, J Wadsley, D Führer, B Keam… - … England Journal of …, 2023 - Mass Medical Soc
Background Selpercatinib, a highly selective, potent RET inhibitor, has shown efficacy in
advanced RET-mutant medullary thyroid cancer in a phase 1–2 trial, but its efficacy as …
advanced RET-mutant medullary thyroid cancer in a phase 1–2 trial, but its efficacy as …
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
…, DW Bowles, CS Baik, D Adkins, B Keam… - The lancet Diabetes & …, 2021 - thelancet.com
Background Oncogenic alterations in RET represent important therapeutic targets in thyroid
cancer. We aimed to assess the safety and antitumour activity of pralsetinib, a highly potent, …
cancer. We aimed to assess the safety and antitumour activity of pralsetinib, a highly potent, …
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
…, L Faoro, K Banerjee, JW Oliver, B Keam… - The Lancet …, 2021 - thelancet.com
Background Patients with radioiodine-refractory differentiated thyroid cancer (DTC) previously
treated with vascular endothelial growth factor receptor (VEGFR)-targeted therapy have …
treated with vascular endothelial growth factor receptor (VEGFR)-targeted therapy have …
[HTML][HTML] Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE …
Background Second-line treatment options for advanced head and neck squamous cell
carcinoma (HNSCC) are limited. The phase Ib KEYNOTE-012 study evaluated the safety and the …
carcinoma (HNSCC) are limited. The phase Ib KEYNOTE-012 study evaluated the safety and the …
First-line Pembrolizumab versus Pembrolizumab plus chemotherapy versus chemotherapy alone in non–small-cell lung cancer: a systematic review and network meta …
Background This study aimed to comprehensively review the available evidence regarding
the efficacy of first-line pembrolizumab for advanced/metastatic non–small-cell lung cancer (…
the efficacy of first-line pembrolizumab for advanced/metastatic non–small-cell lung cancer (…
[PDF][PDF] Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas
Purpose Histologic transformation of EGFR mutant lung adenocarcinoma (LADC) into small-cell
lung cancer (SCLC) has been described as one of the major resistant mechanisms for …
lung cancer (SCLC) has been described as one of the major resistant mechanisms for …
[HTML][HTML] The effect of induction chemotherapy using docetaxel, cisplatin, and fluorouracil on survival in locally advanced head and neck squamous cell carcinoma: a …
Purpose The purpose of this study was to compare the survival of patients with locally
advanced head and neck squamous cell carcinoma (LA-HNSCC) undergoing concurrent …
advanced head and neck squamous cell carcinoma (LA-HNSCC) undergoing concurrent …